Flibanserin Fails To Improve Sexual Desire, FDA Advisory Committee Says
This article was originally published in The Pink Sheet Daily
Boehringer Ingelheim unable to show sufficient efficacy for Girosa in hypoactive sexual desire disorder in women.
You may also be interested in...
In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication
Panel’s vote to approve Sprout’s female sexual dysfunction drug is conditioned on a REMS and possible contraindication with alcohol use; questions about drug’s date rape potential, breast cancer finding in mice addressed.
Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed
Advisory committee votes 18-6 to recommend approval of the female sexual dysfunction drug contingent on a risk management plan, despite unease about modest efficacy and risks such as fainting.
Flibanserin Risk Management Challenges: Can A REMS Prevent Alcohol Interactions?
FDA seeks advisory committee views on risk of hypotension and syncope with Sprout’s sexual dysfunction drug flibanserin when used alone or in combination with alcohol, and whether these risks outweigh ‘numerically small’ benefits over placebo.